Table of Contents
Chapter One: Executive Summary
- Scope and Methodology
- Potential Market Opportunity
- Issues and Trends Affecting Market
- Leading Competitors
Chapter Two: Introduction Drugs in Phase III Development
- Introduction
- Drug Development Overview
- Phases of Drug Development
- Benefits and Risks of Phase III Development
- Benefits
- Risks
- Randomization
- Clinical Trial Protocol
- Orphan Drugs
- Fast Track Drug Status
- Biotechnology Drug Development
- Mergers, Acquisitions, and Collaborations
- Contributors To R&D Success
- R&D Spending
- Contract Research Organizations
Chapter Three: Cardiovascular Drugs: Phase III Development Analysis
- Overview
- Heart
- Circulatory System
- Cardiac Cycle
- Isovolumic Contraction
- Ventricular Ejection
- Isovolumic Relaxation
- Coronary Circulation
- Cardiac Myocytes
- o
- Contraction
- Calcium Role in Contraction
- Relaxation
- Cardiac Energy Metabolism
- Cardiac Output
- Conditions
- Angina Pectoris
- Arrhythmia
- Atherosclerosis
- Congestive Heart Failure
- Coronary Artery Disease
- Hypertension
- Myocardial Infarction
- Incidence of Conditions
- Products in Development
- AGI-1067
- Alfimeprase
- Ambrisentan
- Angiomax
- Atrixra
- Azimilide
- Celacade
- Clevelox
- Conivaptan
- CP-529, 414 (Torcetrapib/Atorvastatin)
- Dabigatran Extexilate
- Darusentan
- Dronedarone
- Exanta
- Enoximone capsules
- Idraparinux
- Integrilin
- Lercanidipine (Zanidip)
- OPC-41061
- Pexelizumab
- Prasugrel
- Propiony-l-carnitine
- Ranexa
- Resten NG
- RSD 1235 IV
- Simdax
- SPP101
- Tecadenoson
- Tedisamil (Pulzium)
- Thelin
- Market Size and Growth
- Competitive Analysis
Chapter Four: Neuropsychotherapeutic Drugs: Phase III Development
Analysis
- Overview
- Structural Organization of the Neurological System
- Types of Neuropsychotherapeutic Diseases and Disorders
- Alzheimer's Disease and Dementia
- Traumatic Brain Injury
- Cerebrovascular Disease and Stroke
- Ischemic Stroke
- Hemorrhagic Stroke
- Cerebral Palsy
- Parkinson's Disease
- Huntington's Disease
- Myasthenia Gravis
- Tic and Tourette's Syndrome
- Periodic Limb Movement Disorder and Restless Leg Syndrome
- Seizures
- Generalized Seizures
- Partial Seizures
- Aura/Prodrome
- Multiple Sclerosis
- Amyotrophic Lateral Sclerosis
- Spinal Cord Injury
- Guillian-Barre Syndrome
- Bell's Palsy
- Anxiety Disorders
- Panic Disorder
- Post-traumatic Stress Disorder
- Specific and Social Phobias
- Attention Deficit Hyperactivity Disorder
- Bipolar Disorder
- Cyclothymic Disorder
- Borderline Personality Disorder
- Depression
- Eating Disorders
- Anorexia Nervosa
- Bulimia Nervosa
- Obsessive-Compulsive Disorder
- Schizophrenia
- o
- Sleep Disorders
- Insomnia
- Narcolepsy
- Parasomnia
- Substance Abuse
- Alcohol Abuse
- Drug Abuse
- Incidence of Conditions
- Products in Development
- AERx Inhaled Morphine
- Alcar
- ALGRX 3268
- Alzhemed
- Ampligen
- Antegren
- Aquavan
- Asenapine
- Bicifadine
- Bifeprunox
- CEP 1347
- Cerovive
- Chronogesic
- Citicoline
- Corlux
- DAS-431
- DU 127090
- DVS-223
- Dynastat
- Fampridine
- Flurizan
- Gaboxadol
- Iloperidone
- Indiplon
- KW-6002
- Lacosamide
- Miraxion
- MT 100
- MT 300
- Mylinax
- Neurodex
- NGX-4010
- NRP104
- Nuvigil
- ONO-2506
- Org 25969
- Oxytrex
- Pagoclone
- Phenserine
- PRX-00023
- Rapinyl
- Rasagiline
- Remoxy
- ReoPro
- Requip CR
- Rotigotine CDS
- Saredutant
- SGS111
- Silenor
- SLV308
- SPD 503
- Spheramine
- SR58611
- Teriflunomide
- Tramadol
- Trexima
- Xaliproden
- Zelpar
- Market Size and Growth
- Competitive Analysis
Chapter Five: Infectious Disease: Phase III Development Analysis
- Overview
- Conditions
- Fungi
- Viruses
- Hepatitis
- Hepatitis A
- Hepatitis B
- Hepatitis C
- Hepatitis D
- Hepatitis E
- Hepatitis G
- Herpes Simplex
- Epstein-Barr Virus (Mononucleosis)
- Influenza
- Other Significant Viruses
- Human Papilloma Virus
- Cytomegalovirus
- Respiratory Syncytial Virus
- Hantavirus
- Yellow Fever
- Rotavirus
- Parvovirus
- Incidence of Conditions
- Products in Development
- ABT-773
- ACAM2000
- Amoxicillin PULSYS
- Anidulafungin
- Aplaviroc
- AzaSite
- Aztreonam Lysinate
- Buffer Gel
- Ceftobiprole (BAL5788)
- Cervarix
- Cubicin (daptomycin for injection)
- Dalbavancin
- Doripenem
- Extina
- Faropenem daloxate
- Gardasil
- Garenoxacin
- Helicide
- Hyphanox
- IFN-alpha Lozenge
- Influvac TC
- Iseganan
- Interferon Alfacon/Ribaviron Combination
- Macrotac
- ME-609
- Maraviroc
- Multiferon
- MX-226 (CPI-226)
- Neuprex
- Noxafil
- Oracea
- Oritavancin
- PolyphenonE Ointment
- PRO 2000
- Ramoplanin
- Retapamulin
- Rotarix
- SAVVY
- Simplirix
- SPO1A
- StaphVAX
- Streptorix
- T-3811
- Telavancin
- Telbivudine
- Tifacogin
- Tolevamer
- Tripranavir
- Ushercell
- Veronate
- Viramidine
- Zadaxin
- Market Size and Growth
- Competitive Analysis
Chapter Six: Cancer Drugs: Phase III Development Analysis
- Overview
- Biochemistry of Cancer Cells
- Carcinogen Metabolism
- Causes of Cancer Growth
- Environmental Factors, DNA, RNA
- Cellular Oncogenes
- Tumor Suppressor Genes
- Types of Cancer
- Bladder/Urinary Cancer
- Breast Cancer
- Cervical Cancer
- Colorectal Cancer
- Endometrial (Uterine) Cancer
- Esophageal Cancer
- Head and Neck
- Kidney
- Leukemia
- Liver
- Lung Cancer
- Lymphoma
- Melanoma
- Multiple Myeloma
- Neuroblastoma
- Ovarian Cancer
- Pancreatic Cancer
- Prostate Cancer
- Stomach Cancer
- Incidence of Conditions
- Products in Development
- Acapodene
- Advexin
- Allovectin-7
- Alvocidib
- AMD-3100 (Mozobil)
- Arzoxifene
- Atamestane
- Avastin
- Avicine
- Biovaxid
- Canvaxin
- Ceplene
- Cintredekin besudotox (IL13-PE38)
- Cloretazine
- CoFactor
- Cotara
- DCVAX -Prostate
- Doxil
- DTI 015
- Edotecarin
- Efaproxyn
- FavId
- Genasense
- Glufosfamide
- GMK Therapeutics Vaccine
- GVAX Prostate
- HuMax CD4
- IGN101
- Insegia
- Ixabepilone
- Javlor
- Junovan
- Lapatinib
- Lasofoxifene
- MDX-010
- MyVax
- Neovastat
- Nexavar (previously BAY 43-9006) (Sorafinib)
- NOV-022
- Onconase
- Oncophage
- OncoVax
- Orathecin
- OvaRex
- Panitumumab
- Panvac-VF
- Rencarex
- Satraplatin
- Sipuleucel-T (Provenge)
- STR
- Tavocept
- Taxoprexin
- Telcyta
- Temsirolimus
- TheraCIMhR3(Nimotuzunab)
- Thymitaq
- TransMID-R
- Vatalanib
- Vinorelbine IV
- Xcytrin
- Xerecept
- XL119
- Xorane
- XRP9881
- Xyotax
- Yondelis
- Zactima
- Zarnestra
- ZYC101a
- Market Size and Growth
- Competitive Analysis
Chapter Seven: Other Drugs: Phase III Development Analysis
- Overview
- Conditions
- Types of Conditions, Diseases and Disorders
- Diabetes
- Irritable Bowel Syndrome /Crohn's Disease
- Psoriasis
- Rheumatoid Arthritis
- Osteoporosis
- COPD/Asthma
- Incidence of Conditions
- Products in Development
- 406381
- Aclasta
- Acomplia
- AERx iDMS
- Alicaforsen
- Alista
- Allermist
- Alprox TD
- Alvesco
- ALX-0600
- AMG 162 (Denosumab)
- Aridol
- Arxxant
- Arformoterol
- Asoprisnil
- Axokine
- Bazedoxifene
- Belatacept
- Bio-E-Gel
- Biopten
- Bronchitol
- CDP 870
- Ceprotin
- Chrysalin
- Cilansetron
- Cimzia
- Cordase
- CS-917
- Dapoxetine
- Daxas
- DE-085
- Dexloxiglumide
- DPP4 Inhibitor Oral(Saxasliptin)
- E2/DNG Pill
- Eculizumab
- Evamist
- Exanatide
- Exubera
- FC Patch
- Ferumoxytol
- Fersterodine
- FIBRILLEX
- Formoterol HFA ( Fordil Certihaler)
- Fortigel
- Galida
- Human Growth Hormone
- ICA-17043
- IoGen
- ISV-205
- Itax
- LAF237
- Lasofoxifene (Oporia)
- LEA29Y
- LibiGel
- Librel
- Livial
- Lucentis
- Menopausal Levonorgestrel System
- Mepolizumab
- Methylnaltrexone
- MK-0431(Sitagliptin)
- Muraglitazar (Pargluva)
- NovoMix 50 and 70
- Onercept
- OPC-6535
- Oral Calcitonin
- OrBec
- Oxygent
- Pennsaid Topical Solution
- Phenoptin
- PhotoPoint
- PHP
- Posurdex
- PREOS
- Prexige
- Primolux
- PTI-901
- QAB149
- Rebamipide
- ReFacto AF
- Retanne
- SPD 476
- SPI-0211/RU0211 (Lubiprostone)
- SR 121463
- Stannsoporfin (Stanate)
- Starlix and Diovan
- Tanaproget
- Teduglutide
- Terlipressin
- Tolevamer
- Tostrelle
- VP002
- XP12B
- YAZ
- Zelnorm
- Market Size and Growth
- Competitive Analysis
| 
View Cart
